[1] Sharma K,Kass DA.Heart failure with preserved ejection fraction:mechanisms,clinical features,and therapies[J].Circ Res,2014,115(1):79-96.
[2] Yancy CW, Jessup M,Bozkurt B,et al.2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J].Circulation,2013,128(16):240-327.
[3] Garlanda C, Bottazzi B, Bastone A,et al.Pentraxins at the crossroads between innate immunity, inflammation,matrix deposition,and female fertility[J].Annu Rev Immunol,2005,23:337-366.
[4] Inforzato A,Peri G,Doni A,et al.Structure and function of the long pentraxin PTX3 glycosidic moiety: fine-tuning of the Interaction with C1q and Complement Activation[J].Biochemistry, 2006,45(38):11540-11551
[5] Presta M,Camozzi M,Salvatori G,et al.Role of the soluble pattern recognition receptor PTX3 in vascular biology[J].J Cell Mol Med,2007,11(4):723-738.
[6] Jaillon S,Peri G,Delneste Y,et al.The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps[J].J Exp Med,2007,204(4):793-804.
[7] Doni A,Mantovani G,Porta C,et al.Cell-specific regulation of PTX3 by glucocorticoid hormones in hematopoietic and nonhematopoietic cells[J].J Biol Chem,2008,283(44):29983-29992.
[8] Norata GD,Marchesi P,Pirillo A,et al.Long pentraxin3,a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells[J].Arterioscler Thromb Vasc Biol,2008,28(5):925-931.
[9] Iwasaki A,Medzhitov R.Regulation of adaptive immunity by the innate immune system[J].Science, 2010,327(5963):291-295.
[10] Reading PC,Bozza S,Gilbertson B,et al.Antiviral activity of the long chain pentraxin PTX3 against influenza viruses[J].J Immunol,2008,180(5):3391-339.
[11] Doni A, Garlanda C, Bottazzi B,et al.Interactions of the humoral pattern recognition molecule PTX3 with the complement system[J].Immunobiology,2012,217(11):1122-1128.
[12] Nauta AJ,Bottazzi B,Mantovani A,et al.Biochemical and functional characterization of the interaction between pentraxin 3 and C1q[J].Eur J Immunol,2003,33(2):465-473.
[13] Baruah P, Dumitriu IE, Peri G,et al.The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells[J].J Leukoc Biol,2006, 80(1):87-95.
[14] Ma YJ,Doni A,Hummelshoj T,et al.Synergy between ficolin-2 and pentraxin 3 boosts innate immune recognition and complement deposition[J].J Biol Chem,2009,284(41):28263-28275.
[15] Deban L,Jaillon S,Garlanda C,et al.Pentraxins in innate immunity:lessons from PTX3[J].Cell Tissue Res,2011,343(1):237-249.
[16] Braunschweig A,Jozsi M.Human pentraxin 3 binds to the complement regulator c4b-binding protein[J].PLoS One,2011,6(8):e23991.
[17] Deban L,Russo RC,Sironi M,et al.Regulation of leukocyte recruitment by the long pentraxin PTX3[J].Nature Immunol,2010,11(4):328-334.
[18] Rusnati M,Camozzi M,Moroni E,et a1.Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis[J].Blood,2004,104(1):92-99.
[19] Camozzi M,Zacchigna S,Rusnati M,et a1.Pentraxin 3 inhibits fibroblast growth factor-2 dependent activation of smooth muscle cells in vitro and neointima formation in vivo[J]. Arteriostler Thromb Vasc Biol,2005,25(9):1837-1842.
[20] Suzuki S,Shishido T,Funayama A,et al.Long pentraxin PTX3 exacerbates pressure overload- induced left ventricular dysfunction[J].PLoS One,2013,8(1):e53133.
[21] Suzuki S,Takeishi X,Niizeki T,et al.Pentraxin 3,a new marker for vascular infammation, predicts adverse clinical outcomes in patients with heart failure[J].Am Heart J,2008,55(1): 75-81.
[22] Duran S,Duran I,Kaptanagasi FA,et al.The role of Pentraxin 3 as diagnostic value in classification of patients with heart failure[J].Clin Biochem,2013,46(12):983-987.
[23] Matsubara J,Sugiyama S,Nozaki T,et al.Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction[J].J Am Coll Cardiol,2011,57(7):861-869.
[24] Latini R,Gullestad L,Masson S,et al.Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials[J].Eur J Heart Fail,2012,14(9):992-999.
[25] Matsubara J,Sugiyama S,Nozaki T,et al.Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction[J].J Am Heart Assoc,2014,3(4):e000928. |
